DiaMedica reports Q2 2026 results, adds FGR enrollment and PE dose plans

DiaMedica Therapeutics provided a business update and reported second quarter 2026 financial results on August 10, 2026, covering its DM199 programs in preeclampsia, fetal growth restriction (FGR) and acute ischemic stroke.

In FGR, the company said enrollment of the first of three planned cohorts has been completed, consisting of 6 participants at the 5 µg/kg dose level, marking the first time DM199 has been used to treat early-onset fetal growth restriction patients.¹ A key opinion leader call is being scheduled in September with principal investigator Dr. Cathy Cluver to discuss topline results from that first cohort.¹

In preeclampsia, DiaMedica said Part 1a testing showed a mean 29.1 mmHg reduction in systolic blood pressure from a baseline mean of 169.3 mmHg (p<0.001) and a 17.0 mmHg reduction in diastolic blood pressure from a baseline mean of 103.7 mmHg (p<0.001), measured five minutes after IV infusion, in the combined final, highest-dose cohorts (n=15).¹ Systolic pressure stayed below 160 mmHg at all measured time points over 24 hours (p<0.01).¹ The company said it is preparing a concurrent open-label, three-dose Phase 2 study in early-onset preeclampsia in North America and the United Kingdom to help select a dose for Phase 3.¹ Separately, Health Canada authorized an open-label, sequential-cohort Phase 2 dose-finding study enrolling about 30 early-onset preeclampsia patients across three dose levels, with first dosing expected in Canada in the fourth quarter of 2026 and a UK expansion planned later this year.¹ On the U.S. path, after receiving FDA feedback in June 2026 on required reproductive toxicity data, DiaMedica said its completed rat study could be sufficient for an IND if it can show adequate drug exposure, enzyme activity and pharmacologic effect in rats.¹

For the stroke program, enrollment in the Phase 2/3 ReMEDy2 trial has passed 85% of the 200 participants needed to trigger a prespecified interim analysis, with about 70 active sites across the US, Canada, the UK and six European countries, and readout expected in early 2027.¹

Financially, the company held $43.5 million in cash, cash equivalents and short-term investments as of June 30, 2026, versus $59.9 million at year-end 2025, which it said should fund operations through 2027.¹